Becton Dickinson & Co. BioGX SARS-CoV-2 Reagents for BD MAX System-IVD PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal specimens Catalog Number: 444213 Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
BioGX SARS-CoV-2 Reagents for BD MAX System-IVD PCR test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal specimens Catalog Number: 444213
Brand
Becton Dickinson & Co.
Lot Codes / Batch Numbers
Not specified in FDA notice. Check official source for details.
Products Sold
Lot Numbers/Exp. Date: Lot Number Expiration Date K20-347 1/23/2021 K20-348 1/23/2021 K20-352 1/24/2021 K20-353 1/24/2021 K20-354 1/24/2021 K20-355 1/25/2021 K20-357 1/25/2021 K20-356 1/25/2021 K20-358 1/26/2021 K20-366 1/28/2021 K20-367 1/29/2021 K20-373 1/30/2021 K20-376 1/31/2021 K20-377 1/31/2021 K20-382 2/1/2021 K20-378 2/2/2021 K20-379 2/2/2021 K20-380 2/3/2021 K20-381 2/3/2021 K20-385 2/5/2021 K20-386 2/6/2021 K20-538 3/1/2021 K20-576 3/20/2021 K20-577 3/20/2021 K20-578 3/20/2021 K20-565 3/21/2021 K20-566 3/21/2021 K20-567 3/21/2021 K20-568 3/21/2021 K20-515 3/24/2021 K20-516 3/24/2021 K20-511 3/27/2021 K20-512 3/27/2021 K20-517 3/28/2021 K20-545 3/28/2021 K20-546 3/28/2021 K20-547 3/28/2021 K20-548 3/28/2021 K20-549 3/28/2021 K20-536 3/29/2021 K20-537 3/29/2021 K20-518 4/1/2021 K20-522 4/1/2021 K20-520 4/2/2021 K20-521 4/2/2021 K20-523 4/2/2021 K20-525 4/2/2021 K20-528 4/3/2021 K20-529 4/3/2021 K20-530 4/3/2021 K20-570 4/3/2021 K20-514 4/4/2021 K20-560 4/4/2021 K20-519 4/5/2021 K20-561 4/5/2021 K20-562 4/5/2021 K20-629 4/5/2021 K20-630 4/5/2021 K20-550 4/6/2021 K20-551 4/6/2021 K20-552 4/6/2021 K20-553 4/7/2021 K20-533 4/8/2021 K20-524 4/9/2021 K20-526 4/9/2021 K20-531 4/9/2021 K20-532 4/9/2021 K20-539 4/10/2021 K20-540 4/10/2021 K20-569 4/11/2021 K20-571 4/11/2021 K20-541 4/12/2021 K20-542 4/12/2021 K20-543 4/12/2021 K20-554 4/12/2021 K20-555 4/12/2021 K20-556 4/12/2021 K20-579 4/12/2021 K20-580 4/12/2021 K20-527 4/13/2021 K20-563 4/13/2021 K20-564 4/13/2021 K20-544 4/14/2021 K20-534 4/16/2021 K20-572 4/16/2021 K20-573 4/16/2021 K20-557 4/17/2021 K20-558 4/17/2021 K20-559 4/17/2021 K20-513 4/18/2021 K20-535 4/20/2021 K20-581 4/21/2021 K20-582 4/21/2021 K20-594 4/21/2021 K20-603 4/21/2021 K20-587 4/22/2021 K20-588 4/22/2021 K20-589 4/22/2021 K20-640 4/22/2021 K20-641 4/22/2021 K20-642 4/22/2021 K20-574 4/23/2021 K20-575 4/24/2021 K20-583 4/25/2021 K20-584 4/25/2021 K20-585 4/25/2021 K20-586 4/25/2021 K20-596 4/26/2021 K20-592 4/27/2021 K20-590 4/28/2021 K20-591 4/28/2021 K20-622 4/29/2021 K20-623 4/29/2021 K20-593 4/30/2021 K20-597 5/1/2021 K20-598 5/1/2021 K20-609 5/1/2021 K20-610 5/1/2021 K20-611 5/1/2021 K20-612 5/1/2021 K20-618 5/1/2021 K20-619 5/1/2021 K20-599 5/2/2021 K20-604 5/2/2021 K20-605 5/2/2021 K20-627 5/2/2021 K20-628 5/2/2021 K20-602 5/3/2021 K20-607 5/3/2021 K20-608 5/3/2021 K20-601 5/4/2021 K20-606 5/4/2021 K20-595 5/5/2021 K20-613 5/6/2021 K20-614 5/6/2021 K20-624 5/7/2021 K20-625 5/7/2021 K20-615 5/9/2021 K20-616 5/9/2021 K20-617 5/9/2021 K20-621 5/9/2021 K20-600 5/10/2021 K20-620 5/11/2021 K20-632 5/11/2021 K20-633 5/11/2021 K20-626 5/12/2021 K20-631 5/13/2021 K20-638 5/13/2021 K20-639 5/13/2021 K20-634 5/14/2021 K20-635 5/14/2021 K20-643 5/14/2021 K20-636 5/16/2021 K20-637 5/17/2021 UDI: 382904442132
Becton Dickinson & Co. is recalling BioGX SARS-CoV-2 Reagents for BD MAX System-IVD PCR test intended for the qualitative detection of due to BioGX SARS-CoV-2 Reagents for BD MAX" System rehydration buffer tubes were not adequately sealed causing some tubes to be partially filled or empty up. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
BioGX SARS-CoV-2 Reagents for BD MAX" System rehydration buffer tubes were not adequately sealed causing some tubes to be partially filled or empty upon use. A partially filled or empty rehydration buffer tube may lead to an Unresolved (UNR) result on the BD MAX" System
Recommended Action
Per FDA guidance
BD issued Urgent Medical Device Correction letter on March 24, 2021 FedEx tracked. Letter states reason for recall, health risk and action to take: 1. Inspect rehydration buffer tubes prior to use for the specific catalog and lot numbers listed below in Attachment A and destroy any products containing partially filled or empty tubes following your institutions process for destruction. 2. Share and Post this medical device recall notification within your facility network to ensure users inspect tubes prior to use. 3. Complete the attached Customer Response Form and return to the BD contact noted on the form whether or not you have any of the impacted material so that BD may acknowledge your receipt of this notification per FDA requirements and subsequently process your product replacement, if required. 4. Report any adverse health consequences experienced with the use of this product to BD. Events may also be reported to the FDA's MedWatch Adverse Event Reporting program via: Actions Taken by BD: 1. Corrective actions have been initiated to prevent recurrence of the identified root cause. 2. BD will provide a product replacement for all destroyed inventory. If you require further assistance, please contact: BD Contact US Contact Information Outside of US BD Customer/ Technical Support 800-638-8663 Monday Friday 7:00am and 7:00pm EST For customers outside the US, contact the local BD representative or distributor.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026